title: [Cinacalcet treatment for secondary hyperparathyroidism in dialysis patients in real-world clinical practice - the ECHO observational study: French experience].
abstract: In chronic kidney disease patients with secondary hyperparathyroidism (SHPT), the recommended K/DOQI™ target serum levels of parathyroid hormone (PTH), calcium (Ca) and phosphorus (P) are difficult to reach and maintain stable. We present the results of the French cohort from the European study ECHO which investigated the use and effectiveness of cinacalcet in real-world clinical practice.
  
  
  METHODS
  An observational study of the SHPT management in dialysis patients, partially retrospective (from 6 months prior to cinacalcet initiation) and partially prospective (up to 12 months of cinacalcet treatment).
  
  
  RESULTS
  Four hundred and eighty-five French patients were enrolled from 44 centres. Cinacalcet was given in combination with active vitamin D treatment (39%) and phosphate binders (87%). After 12 months, the proportion of patients reaching recommended K/DOQI™ target levels had increased from 2.5% to 28.8% for PTH, from 46.8% to 50.1% for Ca, from 40.0% to 49.9% for P and 54.8% to 77.7% for the CaxP product. The proportions of patients using active vitamin D and sevelamer decreased by 6% and 20% respectively. Adverse events were reported in 37 (7.6%) patients, mainly nausea (2.1%), vomiting (2.1%) and dyspepsia (1.2%).
  
  
  CONCLUSIONS
  The results of this study are consistent with data from controlled and randomized studies showing that cinacalcet increases the proportion of patients achieving the K/DOQI™ targets for PTH, Ca, P and CaxP in real-world clinical practice.
authors.affiliation: Néphrologie et dialyse, clinique du Landy, 23, rue du Landy, 93400 Saint-Ouen, France. urena.pablo@wanadoo.fr
authors.forename: P
authors.initials: P
authors.lastname: Ureña
authors.forename: D
authors.initials: D
authors.lastname: Fouque
authors.forename: P
authors.initials: P
authors.lastname: Brunet
authors.forename: M
authors.initials: M
authors.lastname: Touam
authors.forename: J-C
authors.initials: JC
authors.lastname: Réglier
mesh_terms: D000368:Aged; D057966:Calcimimetic Agents / Q000627:therapeutic use*; D002614:Chelating Agents / Q000627:therapeutic use; D000069449:Cinacalcet; D005260:Female; D005602:France; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy* / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000627:therapeutic use*; D011073:Polyamines / Q000627:therapeutic use; D011446:Prospective Studies; D006435:Renal Dialysis; D012189:Retrospective Studies; D000069603:Sevelamer; D014807:Vitamin D / Q000627:therapeutic use; D014815:Vitamins / Q000627:therapeutic use
chemical_list: D057966:Calcimimetic Agents; D002614:Chelating Agents; D009281:Naphthalenes; D011073:Polyamines; D014815:Vitamins; D014807:Vitamin D; D000069603:Sevelamer; D000069449:Cinacalcet